Neuren’s (ASX:NEU) drug gets approval from US patent to treat autism  

Highlights 

  • Neuren will start Phase two trials of its second drug candidate, NNZ-2591, for Angelman syndrome, Pitt Hopkins syndrome, Phelan-McDermid syndrome, and Prader-Willi syndrome. 
  • Considering the urgent unmet need, all six programs have been given “orphan drug” designation in the US.
  • Orphan drug designation offers incentives to promote the development of therapies for critical and rare diseases.

ASX-listed biopharmaceutical Company Neuren Pharmaceuticals Limited (ASX:NEU) announced on Monday that it has received a Notice of Allowance from the US Patent and Trademark Office for a new patent that covers NNZ-2591 to treat autism.

The patent term, titled “Bicyclic compounds and methods for their use in treating autism” extends to July 2034.

Similar claims have previously been granted in Europe and Japan. Neuren is currently developing NNZ-2591 to treat Phelan-McDermid, Angelman, Pitt Hopkins and Prader-Willi syndromes, four lifelong severe neurological disorders that emerge during early childhood.  

About Neuren   

The Company is growing two new drug remedies to treat various neurological severe disorders that develop in early childhood, none of which have licensed medicines. At present, the main compound, trofinetide, is in the third phase of the clinical trial for Rett syndrome with best outcomes anticipated in Q4 2021 and has concluded a Phase 2 clinical trial in Fragile X syndrome.

NEU has awarded an exclusive licence to Acadia Pharmaceuticals Inc. to produce and market trofinetide in North America while preserving all rights outside North America.  In addition, NEU is planning to begin Phase two trials of its second drug candidate, NNZ-2591, for Angelman syndrome, Pitt Hopkins syndrome, Phelan-McDermid syndrome, and Prader-Willi syndrome.

Considering the urgent unmet need, all six programs have been given “orphan drug” designation in the US. Orphan drug designation offers incentives to promote the development of therapies for critical and rare diseases.  

Meanwhile, the stock NEU ended 4.477% higher at AU$2.100 per share on the ASX. 

Read More: Aldoro (ASX:ARN) expands Windimurra Fairway position with Acquisition 

 Bottom Line:  

The Company believes that the method of action of NNZ-2591 has a vast utility in neurodevelopmental ailments. Furthermore, given that autism is estimated to affect one in 160 children, the grant of this critical US patent could potentially enable a tremendous future opportunity for the Company as the awareness about causes of autism increases.  

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK